@FierceMedDev: FDA: Spending cuts will delay product approvals. Item | Follow @FierceMedDev
@MarkHFierce: Fierce 15 company CardioKinetix nailed down the second half of a $44M Series E. News | Follow @MarkHFierce
@DamianFierce: Have a look at @FierceMedDev's top 10 moneymakers in medical devices. Special Report | Follow @DamianFierce
> Zoll's defibrillators helped double the survival rate of out-of-hospital cardiac arrest, a new study suggests. Release
> A Theragenics ($TGX) subsidiary is rolling out a new line of peripherally inserted central catheters. Item
> Diagnostics maker Cognoptix is kicking off a clinical trial of its Alzheimer's diagnostic that detects a beta amyloid signature in patients' eyes. More
> 2012 Fierce 15 winner T2 Biosystems has secured a patent that will allow it to develop a real-time, in vivo application of its T2MR diagnostics platform. News
> Amedica nailed down a new U.S. patent for an artificial spine disc implant using the company's proprietary Silicon Nitride ceramic material. Release
> The Atlantic takes a look at the FDA's 510(k) loophole that has put many high-risk devices on the market without much clinical evidence of safety and efficacy. Article
> Looking at a meta-analysis of 7 studies, researchers determined that Medtronic's ($MDT) Pillar treatment for obstructive sleep apnea significantly reduced snoring volume. Report
Biotech News
@FierceBiotech: Ignyta, Lieden University team on rheumatoid arthritis biomarker research. Item | Release | Follow @FierceBiotech
@JohnCFierce: Sarepta spikes on disputed report of adverse events for rival GSK drug. Story | Follow @JohnCFierce
@RyanMFierce: Is Africa poised to play a bigger role in drug innovation? From Novartis: More | Follow @RyanMFierce
> Merck's Tredaptive fiasco blamed on adverse reactions to niacin. Article
> Langer biotech Kala earmarks $11.5M round for next-gen ophthalmology drugs. More
> Takeda snags rights to lupus drugs from Seattle upstart in $255M deal. News
Pharma News
@FiercePharma: Trending: Top 10 Pharma Advertising Budgets - 2012. Special Report | Follow @FiercePharma
@EricPFierce: U.S. Supreme Court ruling against Amgen in class action investor case seen as hit to Pharma, other businesses. Story | Follow @EricPFierce
> Valeant Pharmaceuticals ($VRX) swung to a loss in the fourth quarter, thanks to charges related to its Medicis Pharmaceutical buyout. Report | Release
> Indian generics maker Cipla hiked its offer for South Africa's Cipla Medpro by 17%, bringing its bid to $512 million. Report
> Lundbeck won European approval for Selincro, a treatment for alcohol dependency that's key to the Danish drugmaker's growth strategy. Report
> Ipsen posted a full-year loss of €29 million ($37.9 million) after pulling out of the hemophilia treatment market. Report
> An Indian court put Cadila Pharmaceuticals on notice after the drugmaker failed to raise employees' salaries as ordered by an industrial tribunal. Report
Vaccines News
> FDA panel endorses quadrivalents, setting stage for new flu market. Article
> Is it too soon to quit on Nabi's nicotine vaccine? More
> Seasonal flu vaccine only 56% effective. Story
> GSK facing competition from Sanofi's 6-in-1 shot. Item
> After rejection, Dynavax to shoot for limited hep B vaccine approval. Report
Pharma Manufacturing News
> Ranbaxy problems overshadow manufacturing expansion. Article
> Qualicaps adds new technology as part of expansion. Item
> FDA warning to Abbey questions quality of API for sterile drugs. Story
> Hospira manufacturing problems arise at an inopportune time. More
And Finally... Autism shares genetic features with four other psychiatric disorders, including bipolar disorder and schizophrenia. Report